Literature DB >> 29871886

Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia.

Jason C George1, Waleed Zafar2, Ion Dan Bucaloiu1, Alex R Chang3,2.   

Abstract

BACKGROUND AND OBJECTIVES: Rapid correction of severe hyponatremia can result in serious neurologic complications, including osmotic demyelination. Few data exist on incidence and risk factors of rapid correction or osmotic demyelination. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a retrospective cohort of 1490 patients admitted with serum sodium <120 mEq/L to seven hospitals in the Geisinger Health System from 2001 to 2017, we examined the incidence and risk factors of rapid correction and osmotic demyelination. Rapid correction was defined as serum sodium increase of >8 mEq/L at 24 hours. Osmotic demyelination was determined by manual chart review of all available brain magnetic resonance imaging reports.
RESULTS: Mean age was 66 years old (SD=15), 55% were women, and 67% had prior hyponatremia (last outpatient sodium <135 mEq/L). Median change in serum sodium at 24 hours was 6.8 mEq/L (interquartile range, 3.4-10.2), and 606 patients (41%) had rapid correction at 24 hours. Younger age, being a woman, schizophrenia, lower Charlson comorbidity index, lower presentation serum sodium, and urine sodium <30 mEq/L were associated with greater risk of rapid correction. Prior hyponatremia, outpatient aldosterone antagonist use, and treatment at an academic center were associated with lower risk of rapid correction. A total of 295 (20%) patients underwent brain magnetic resonance imaging on or after admission, with nine (0.6%) patients showing radiologic evidence of osmotic demyelination. Eight (0.5%) patients had incident osmotic demyelination, of whom five (63%) had beer potomania, five (63%) had hypokalemia, and seven (88%) had sodium increase >8 mEq/L over a 24-hour period before magnetic resonance imaging. Five patients with osmotic demyelination had apparent neurologic recovery.
CONCLUSIONS: Among patients presenting with severe hyponatremia, rapid correction occurred in 41%; nearly all patients with incident osmotic demyelination had a documented episode of rapid correction. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_06_05_CJASNPodcast_18_7_G.mp3.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Aged; Brain; Central Pontine Myelinolysis; Comorbidity; Demyelinating Diseases; Female; Humans; Incidence; Magnetic Resonance Imaging; Mineralocorticoid Receptor Antagonists; Osmotic Demyelination; Outpatients; Rapid Correction; Retrospective Studies; Schizophrenia; Sodium; hypokalemia; hyponatremia; risk factors

Mesh:

Year:  2018        PMID: 29871886      PMCID: PMC6032596          DOI: 10.2215/CJN.13061117

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  36 in total

Review 1.  Treatment of hyponatremia.

Authors:  Richard H Sterns; John Kevin Hix; Stephen Silver
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients.

Authors:  R D ADAMS; M VICTOR; E L MANCALL
Journal:  AMA Arch Neurol Psychiatry       Date:  1959-02

3.  Benign type of central pontine myelinolysis in alcoholism--clinical, neuroradiological and electrophysiological findings.

Authors:  Hitoshi Mochizuki; Toshihiro Masaki; Tomohiro Miyakawa; Jun Nakane; Akira Yokoyama; Yuji Nakamura; Keiji Okuyama; Keiko Kamakura; Kazuo Motoyoshi; Sachio Matsushita; Susumu Higuchi
Journal:  J Neurol       Date:  2003-09       Impact factor: 4.849

4.  Patients presenting with severe hypotonic hyponatremia: etiological factors, assessment, and outcomes.

Authors:  Thuy Vu; Rosemary Wong; P Shane Hamblin; Jeffrey Zajac; Mathis Grossmann
Journal:  Hosp Pract (1995)       Date:  2009-12

5.  Disorders of plasma sodium.

Authors:  Richard H Sterns
Journal:  N Engl J Med       Date:  2015-03-26       Impact factor: 91.245

6.  Treatment of hyponatremic encephalopathy with a 3% sodium chloride protocol: a case series.

Authors:  Juan Carlos Ayus; Daniel Caputo; Fernando Bazerque; Ricardo Heguilen; Claudio D Gonzalez; Michael L Moritz
Journal:  Am J Kidney Dis       Date:  2014-11-25       Impact factor: 8.860

Review 7.  Risk factors, complication and measures to prevent or reverse catastrophic sodium overcorrection in chronic hyponatremia.

Authors:  Kamel A Gharaibeh; Joseph M Brewer; Mohit Agarwal; Tibor Fülöp
Journal:  Am J Med Sci       Date:  2015-02       Impact factor: 2.378

8.  Osmotic demyelination syndrome following correction of hyponatremia.

Authors:  R H Sterns; J E Riggs; S S Schochet
Journal:  N Engl J Med       Date:  1986-06-12       Impact factor: 91.245

Review 9.  The treatment of hyponatremia.

Authors:  Richard H Sterns; Sagar U Nigwekar; John Kevin Hix
Journal:  Semin Nephrol       Date:  2009-05       Impact factor: 5.299

10.  Cause and prevention of demyelination in a model multiple sclerosis lesion.

Authors:  Roshni A Desai; Andrew L Davies; Mohamed Tachrount; Marianne Kasti; Frida Laulund; Xavier Golay; Kenneth J Smith
Journal:  Ann Neurol       Date:  2016-02-22       Impact factor: 10.422

View more
  17 in total

1.  Derivation and Validation of a Novel Risk Score to Predict Overcorrection of Severe Hyponatremia: The Severe Hyponatremia Overcorrection Risk (SHOR) Score.

Authors:  Jason D Woodfine; Manish M Sood; Thomas E MacMillan; Rodrigo B Cavalcanti; Carl van Walraven
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-12       Impact factor: 8.237

2.  Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.

Authors:  Yukyung Kim; Nari Lee; Kyung Eun Lee; Hye Sun Gwak
Journal:  Eur J Clin Pharmacol       Date:  2020-02-13       Impact factor: 2.953

Review 3.  Criteria for Hyponatremic Overcorrection: Systematic Review and Cohort Study of Emergently Ill Patients.

Authors:  Jason D Woodfine; Carl van Walraven
Journal:  J Gen Intern Med       Date:  2019-08-26       Impact factor: 5.128

Review 4.  Central pontine myelinolysis and the osmotic demyelination syndromes: an open and shut case?

Authors:  Pyari Bose
Journal:  Acta Neurol Belg       Date:  2021-03-13       Impact factor: 2.396

5.  Risk factors for overcorrection of severe hyponatremia: a post hoc analysis of the SALSA trial.

Authors:  Huijin Yang; Songuk Yoon; Eun Jung Kim; Jang Won Seo; Ja-Ryong Koo; Yun Kyu Oh; You Hwan Jo; Sejoong Kim; Seon Ha Baek
Journal:  Kidney Res Clin Pract       Date:  2022-02-22

6.  Normal Correction of Sodium Leading to Central Pontine Demyelinosis: A Rare Occurrence.

Authors:  Fasih Sami Siddiqui; Zarmina Javed; Ujala Mahmood; Izza Saeed; Yusaf F Qasim; Muhammad Saim Bin Saeed
Journal:  Cureus       Date:  2018-09-04

7.  The use of mannitol in cardiopulmonary bypass prime solution-Prospective randomized double-blind clinical trial.

Authors:  Magnus Ljunggren; Andreas Sköld; Alain Dardashti; Snejana Hyllén
Journal:  Acta Anaesthesiol Scand       Date:  2019-07-29       Impact factor: 2.105

8.  The Effect of the Dose of Isotonic Saline on the Correction of Serum Sodium in the Treatment of Hypovolemic Hyponatremia.

Authors:  Jorge Gabriel Ruiz-Sánchez; Diego Meneses; Cristina Álvarez-Escolá; Martin Cuesta; Alfonso Luis Calle-Pascual; Isabelle Runkle
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

9.  Uremia Preventing Osmotic Demyelination Syndrome Despite Rapid Hyponatremia Correction.

Authors:  Srinadh Annangi; Snigdha Nutalapati; Srikanth Naramala; Pradeep Yarra; Khalid Bashir
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

10.  Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.

Authors:  Seon Ha Baek; You Hwan Jo; Soyeon Ahn; Kristianne Medina-Liabres; Yun Kyu Oh; Jung Bok Lee; Sejoong Kim
Journal:  JAMA Intern Med       Date:  2021-01-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.